SCHEDULE: Janus Henderson Boosts INOVIO Stake to 9.99%

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in INOVIO PHARMACEUTICALS, INC., holding 6,666,295 shares of common stock.

Summary

• Janus Henderson Group plc, a Jersey-based entity, has filed a Schedule 13G indicating beneficial ownership of 6,666,295 shares of INOVIO PHARMACEUTICALS, INC. common stock.
• This ownership represents 9.99% of INOVIO's class of securities.
• The reported shares include certain pre-funded and/or common warrants.
• An additional 991,856 Series A and 991,856 Series B common warrants are not reflected in the reported figures due to a beneficial ownership limit of 9.99% upon exercise.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 6,666,295 beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of INOVIO PHARMACEUTICALS, INC.

Sentiment

Score: 7

Explanation: Janus Henderson Group plc's significant beneficial ownership stake in INOVIO PHARMACEUTICALS, INC. indicates institutional interest, which is generally a positive signal for the company, though the filing is purely an ownership disclosure.

Positives

• A significant beneficial ownership stake by a major institutional investor like Janus Henderson Group plc can signal confidence in INOVIO PHARMACEUTICALS, INC.'s long-term prospects.
• The holding of 9.99% of the common stock, inclusive of warrants, demonstrates substantial institutional interest in the company.

Negatives

• The beneficial ownership limit of 9.99% restricts the immediate exercise of an additional 991,856 Series A and 991,856 Series B common warrants, which are not reflected in the reported figures.

Risks

• Janus Henderson's ability to fully exercise all held warrants is constrained by a 9.99% beneficial ownership cap, meaning 1,983,712 additional warrants (991,856 Series A and 991,856 Series B) cannot be immediately converted if it would exceed this threshold.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding INOVIO PHARMACEUTICALS, INC.'s future financial performance or strategic outlook.

Management Comments

• Janus Henderson Group plc certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of INOVIO PHARMACEUTICALS, INC.

Industry Context

Institutional investors frequently take significant stakes in biotechnology and pharmaceutical companies, often reflecting a long-term view on their drug pipelines or market potential. This filing indicates Janus Henderson's continued or increased interest in the sector through INOVIO.

Stakeholder Impact

• Shareholders of INOVIO PHARMACEUTICALS, INC. may view this significant institutional holding as a positive indicator of investor confidence in the company.

Key Dates

Keywords

INOVIO Pharmaceuticals, Janus Henderson, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional investor, warrants